Clinical trials: Hereditary Breast Carcinoma
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Huntington Disease, Hereditary Breast and Ovarian Cancer
Genetic Risk: Whether, When, and How to Tell Adolescents
This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for…
- Conditions
- Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer
- Trial name
- NCT03421327
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Breast Cancer
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
This was a retrospective observational study of patients with advanced breast cancer (BC). This non-interventional study was conducted using discrete structured data and medical record abstraction, if needed, from patients…
- Trial name
- NCT05982886
- Where
- United States
- Volunteers
- 1,093 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Hereditary Diseases
UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research
UPTIDER is a prospective, interventional, non-Investigational Medicinal Product (non-IMP), non-commercial, single centre post-mortem tissue donation program for metastatic breast cancer patients or patients with a germline…
- Trial name
- UPTIDER (NCT04531696)
- Testing
- Blood draw, Post-mortem tissue collection
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Radiation Induced Fibrosis
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients…
- Trial name
- NCT05637216
- Testing
- Losartan 25 milligram capsule
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Shaw Cancer Center
Abnormalities, Radiation-Induced, Atherosclerosis
Radiation Induced Atherosclerosis in Breast Cancer Patients
Radiation induced accelerated atherosclerosis is a well known entity that occurs in different regions, according to the therapy delivered.It is usually begins to be clinically evident several years after the radiation incident…
- Conditions
- Abnormalities, Radiation-Induced, Atherosclerosis, Breast Cancer
- Trial name
- NCT00388713
- Testing
- carotid intima-media thickening ultrasound
- Where
- Israel
- Volunteers
- 350 people
- Sponsor
- Hadassah Medical Organization
Breast Cancer
Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer
Longitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer.
- Trial name
- NCT02125019
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Breast Cancer, Metastatic Triple Negative Breast Cancer
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
The purpose of this study is to determine the safety profile, the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with paclitaxel in metastatic breast cancer (mBC)…
- Trial name
- NCT03411161
- Testing
- Combination therapy (S81694 + paclitaxel) phase I, Paclitaxel, Combination therapy (S81694 + paclitaxel) phase II
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Institut de Recherches Internationales Servier
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Neoplasm Female, Early Detection of Cancer
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women.
- Conditions
- Breast Neoplasm Female, Early Detection of Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Magnetic Resonance Imaging
- Trial name
- NCT06892275
- Testing
- Enhanced Usual Care, Decision Support
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Georgetown University
Familial Breast Cancer, Familial Colorectal Cancer
Direct Information to At-risk Relatives
This study evaluates if uptake of genetic counselling in high-risk families is increased when patients at cancer genetics clinics are being offered healthcare-assisted disclosure to at-risk relatives compared to current standard…
- Conditions
- Familial Breast Cancer, Familial Colorectal Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Breast Cancer
- Trial name
- DIRECT (NCT04197856)
- Testing
- Standard care encouraging family-mediated disclosure of hereditary cancer risk, Offer of health-care assisted disclosure by sending direct letters to at-risk relatives
- Where
- Sweden
- Volunteers
- 490 people
- Sponsor
- Umeå University
Breast Cancer
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
- Trial name
- NCT00285857
- Testing
- Lovastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
HR+ HER2- Breast Cancer
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants…
- Trial name
- NCT07558733
- Testing
- Serabelisib, Sapanisertib, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Faeth Therapeutics
Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Scalable Communication Modalities for Returning Genetic Research Results
Efforts to examine the utility of alternate modalities for genetic results disclosure has widespread implications for how precision medicine research might yield direct health benefits for study participants.
- Trial name
- BWHS RoR (NCT04407611)
- Testing
- Online modality, Genetic counselor follow-up
- Where
- United States
- Volunteers
- 926 people
- Sponsor
- Boston University
Breast Cancer, Ovarian Cancer
Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility
This non-therapeutic trial is for women who have received results of genetic testing for BRCA1/2 mutations. The trial compares decision support tools designed to facilitate informed decision making regarding risk management…
- Trial name
- NCT02133703
- Testing
- Enhanced Internet DA, Internet DA, Enhanced Print DA
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Georgetown University
Breast Cancer, Ovarian Cancer
Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk
We are inviting you to participate in a study of how people who have had genetic counseling for breast/ovarian cancer risk feel about certain reproductive technologies, preimplantation genetic diagnosis (PGD) and prenatal genetic…
- Trial name
- NCT00735150
- Testing
- questionnaire, interview
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Abnormalities, Radiation-Induced
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
Some patients who undergo breast cancer treatment with lumpectomy followed by radiation therapy develop significant late skin and soft tissue changes, resulting in a poor cosmetic outcome.
- Trial name
- NCT00652678
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- State University of New York - Upstate Medical University
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00253539
- Testing
- arzoxifene hydrochloride, tamoxifen citrate
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic